The immunosuppressive tumor microenvironment: more than just immune checkpoints
Cell & Gene Therapy Insights 2019; 5(5), 405–409
Published: 4 July 2019
Professor of Cell & Tissue Therapy at University College London
Mark trained as an immunopathologist at the Royal London Hospital and moved to the Royal Free Hospital/UCL in 1994 to set up the immunotherapy programme in malignant hematology. He has specialist knowledge of cellular therapeutics and is the UK representative on the Joint Accreditation Committee ISCT/EBMT (JACIE), which is responsible for setting and co-ordinating standards for cellular therapies across Europe. Mark holds Qualified Person status for the release of investigational somatic cell therapy medicinal products in the EU and is a Designated Individual under a Human Tissue Authority licence for therapeutic cells. Mark has been a Chief Scientific Officer and Chief Manufacturing Officer since the formation of the InMuneBio in September 2015. Since February 2009, he has also been Director of Cellular Therapy at the Royal Free London NHS Foundation Trust. He received his PhD in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.